Parts of Latin America and the Caribbean have become COVID-19 hot spots. With 8 percent of the world’s population, the region accounts for nearly one-third of all COVID-19 infections and deaths as of late November. Although new infections have slowed on a regional level, ongoing second or third pandemic waves across Europe and the United States could be a sign of things to come. Globally and in Latin America, life will likely not return to normal without an effective vaccine. Naturally acquired herd immunity appears elusive. In this context, herculean R&D efforts have accelerated the race for COVID-19 vaccines at record pace. At least nine candidates are undergoing Phase III clinical trials at the time of writing, including two reporting more than 90 percent efficiency. Despite the considerable progress, the U.S. Food and Drug Administration (FDA) had not approved a vaccine for nonemergency use as of November. Uncertainty and questions have arisen beyond the vaccine efficacy and risks. How can countries and populations quickly and safely access and administer vaccines? Can it be done in a fair and equitable way? When will this happen and at what cost? Will there be enough for everyone? Similar questions also apply to potential COVID-19 therapeutics, test solutions, personal protective equipment (PPE), and ventilators, as witnessed early in the pandemic.

As these under-studied questions come to the fore globally, Latin America must plan ahead with added urgency. The region may face vaccine and related hurdles at a greater scale due to financial, technical, and logistic constraints. Policy decisions and actions today will affect health outcomes in the coming months and years, either curtailing or widening the region’s capacity gaps.

In particular, preparation in nine areas will determine regional success in immediate vaccine planning and longer-term public health. The following pages outline each of these areas, including relevant recent developments, major challenges, and potential remedies. Through this analysis and a resulting set of eight cross-cutting recommendations, this practical policy primer aims to inform regional governments and others critical to mitigating the health effects of COVID-10 in order to better prepare the region for the next set of pandemic-related challenges. The historic magnitude of the ongoing pandemic requires a whole-of-society approach: collaboration among relevant stakeholders from governments, the private sector, multilateral organizations, and civil society will be indispensable.

**VACCINE PRODUCTION AND ACQUISITION**

For many Latin American countries, a two-pronged approach—bilateral and multilateral partnerships—is needed to acquire a sufficient amount of vaccines for their citizens. Bilaterally, countries including Argentina, Brazil, Chile, Mexico, and Peru have secured more than two hundred and eighty-six million potential doses through production or purchase agreements with various pharmaceutical companies. The region’s active participation in advanced clinical trials of vaccines has helped strengthen negotiation positions for access. On the multilateral front, twenty-two Latin American and Caribbean countries will obtain millions of effective doses through the COVAX Facility, a global initiative co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, and the World Health Organization (WHO). Working with a diverse portfolio of vaccine candidates through multiple procurement sources is indispensable because at least some current candidates will fall short of desired safety or efficacy requirements—a normal and historically common outcome. The region could need well over seven hundred million functioning doses to reach a theoretical threshold of herd immunity (60 percent) through vaccination.

There are two ways to acquire vaccines: local production and trade. Each comes with its own set of challenges.

**Local Production**

Producing COVID-19 vaccines is an unprecedented global challenge, prompting the world to double its production over twelve to eighteen months. Latin America is taking part in these global efforts. For instance, Argentina, Brazil, and Mexico have made arrangements with AstraZeneca and the University of Oxford to supply up to four hundred million doses of the AZD1222 vaccine to regional markets. The vaccines will be produced in an mAbxience plant in Garín, Argentina, and then sent to Liomont Laboratories in Ocoyoacac, Mexico, for packaging and distribution.

---


There are, however, several chronic hurdles to expanding local production in Latin America. Vaccines are a highly complex product of advanced manufacturing. Most countries outside Argentina, Brazil, and Mexico do not yet possess the adequate infrastructure or sophistication required to produce or store vaccines at scale. Another key issue to consider is intellectual property (IP) protection, a major concern for multinational pharmaceutical companies. During the first months of the pandemic, a number of regional governments contemplated compulsory licensing measures out of understandable concerns around vaccine accessibility. While well-intentioned, such policies could disincentivize international vaccine makers and investors, who prefer to operate in a regulatory environment with robust patent enforcement.

As with other regions of the world, Latin America has reeled from the disruptions to global supply chains caused by COVID-19. In particular, overreliance on foreign medical supplies is fueling a regional drive toward greater self-sufficiency in pharmaceutical products. This is a warranted strategic ambition and welcome news for overstretched global capacity in the long run. Yet, scaling up regional production takes time and cannot singlehandedly address the ongoing emergency. In the short run, countries must also embrace another option to acquire lifesaving medicines and products: trade, which will be discussed in the next section.11

Over the long run, well-designed industrial, investment, and education policy support is vital to increasing the R&D and production capacity of vaccines, therapeutics, and medicines in Latin America. Value-added cooperation with key international firms brings in investment and generates positive externalities on local skills and knowledge. This, coupled with effective public-private coordination on IP issues, will benefit the regional innovation ecosystem which also encompasses many other high-value-add sectors.

Trade

For much of the region with limited manufacturing capacity, trade will be the most realistic pathway to meeting domestic vaccine needs during the current crisis. Even for major vaccine producers in Latin America, trade is of paramount importance. Vaccines are a highly complex compound involving numerous ingredients and stages of production. Few countries in the world possess all the necessary specializations and basic materials to produce a competitive and fully "local" vaccine. A made-in-Latin-America vaccine could entail active pharmaceutical ingredients (APIs) from China or formulation development in India, as well as adjuvants from Chile processed in Sweden.12 The import of intermediate goods is critical to the seamless production and assembly of final goods (vaccines) used for domestic consumption or export.

Given the globalized nature of vaccine manufacturing, governments in Latin America and beyond must ensure unimpeded trade flows across borders. Protectionist temptations can be hard to resist amidst global shortages, especially for countries with greater vaccine self-sufficiency. But these measures rarely pan out as desired and could result in dire regional and global consequences, including an unfortunate scenario of "vaccine nationalism."13

The breakdown of global trade in medical supplies earlier this year provided a fresh reminder of the still-present risks of protectionism. In March and April, for instance, eighty countries imposed export restrictions on medical supplies and equipment.14 This included at least seven countries in Latin America and the Caribbean region, as well as the world’s top three suppliers (China, the United States, and the European Union (EU)), which collectively account for 68.2 percent of regional imports of these critical goods.15 To protect lives and livelihoods, vicious cycles of commercial isolationism and retaliation must be avoided at all costs.

---

11 While governments could sometimes gravitate toward a more national or regional view on vaccine access, industry tends to take a global approach. Manufacturing networks are usually set up in a globalized way to ensure the safest and fastest supply of a vaccine not only for Latin America, but also other regions around the globe. Most vaccine makers, including some with clinical trials in and supply agreements with Latin America, will plan on producing mostly outside the region.


13 Bollyky and Bown, “The Tragedy.”


Specifically, Latin American and Caribbean policymakers can take actions to tackle shared challenges in trade on at least three levels. First, several viable quick wins exist at the national level. Governments should bring down two-way trade barriers on essential medical products and inputs, including import tariffs and export restrictions. Trade facilitation can reduce additional nontariff barriers through streamlined customs procedures and border crossings, electronic filing, expedited certifications and licensing, etc. Brazil, for instance, suspended anti-dumping and simplified administrative processes for import and export licensing of PPE and medical devices. Similar measures should be upheld to safeguard the trade of vaccines, as well as therapeutics, and other lifesaving products and services.

Second, international coordination between governments can further galvanize and amplify country-level actions. The Joint Ministerial Statement to ensure supply chain connectivity amidst the COVID-19 situation, initiated by Singapore and New Zealand in March, is an example to follow. As of July, ten other countries, including China, have joined the initiative, pledging their commitment to keep trade lines open for essential goods. Two Latin American countries, Chile and Uruguay, have also signed on.

Similarly, multilateral fora such as the Asia-Pacific Economic Cooperation (APEC) and regional integration processes such as Mercosur and the Pacific Alliance are other potential

---

18 Singapore Ministry of Trade and Industry, Singapore concludes.
avenues to crowd in best trade practices. APEC members, including three Latin American countries, have issued at least three official declarations on trade facilitation. The Pacific Alliance is playing a critical role in trade policy coordination in Latin America and internationally through its COVID-19 Action Plan and ASEAN-Pacific Alliance Work Plan.

Third, collaboration between the public and private sectors is imperative. Delayed arrivals and departures of essential goods can be costly, especially for time-sensitive products like vaccines. Most vaccines are transported in refrigerated (or frozen) conditions and have limited room temperature shelf life, e.g., between two to twelve hours for Pfizer and Moderna’s COVID-19 vaccines. Even before COVID-19 disruptions, in 2019, the average time to clear exports through customs in Latin America and the Caribbean region was eight days; the average time associated with border compliance for imports was 2.3 days. Accelerating clearance can be achieved through efficient prioritization, nonintrusive inspection, digitization, etc. In addition, airports, seaports, and border authorities should work closely with logistics companies, vaccine producers, and various types of Authorized Economic Operators (importers, brokers, warehouses, and others). New requirements, processes, schedules, or contingent plans that may arise during the pandemic must be communicated clearly and promptly.

Another key area of public-private collaboration in trade is “hard” infrastructure. Enhanced interconnectivity can revitalize regional exports and intra-regional trade, benefitting pharmaceutical and many other supply chains in Latin America, making them more competitive. A 1 percent reduction in transport costs—achievable through infrastructure improvements—could boost overall manufacturing exports between 2 percent and 7.8 percent in Brazil, Chile, Colombia, Mexico, and Peru. In the context of the COVID-19 pandemic, reduced shipping costs and time benefit not only regional vaccine acquisition and production, but in-country distribution of the vaccines and treatments.

**DISTRIBUTION AND ACCESS**

With numerous agreements to acquire vaccines and treatments upon approval, governments must then face another difficult challenge: ensuring effective and equitable access to these lifesaving products in-country. Obstacles exist in at least two broad areas: distribution and access.

**Distribution**

Latin America faces infrastructure and logistics challenges in distributing critical medical resources. These challenges are especially pronounced in rural and remote areas, including some of the hardest-hit parts of the region. Border towns and indigenous communities in the Amazon have reported high rates of COVID-19 cases and deaths. Logistic insufficiency has strained the already scarce medical supplies in these areas, aggravating outbreaks.

When vaccines become available, their distribution must comply with specific transportation and storage protocols to ensure safety and viability. Cold chain can be a particularly difficult and expensive requirement to satisfy. Most vaccines require a storage temperature of between two and eight degrees Celsius from manufacturer to patient. Select mRNA vaccines, such as the ones currently in trials by Pfizer, require a storage temperature of between two and eight degrees Celsius to ensure safety and viability. Cold chain can be a particularly difficult and expensive requirement to satisfy.

Additional challenges emerge from inequitable purchasing power, as Latin American countries will need to pay more per dose than wealthier nations, potentially exacerbating regional disparities. In the context of the COVID-19 pandemic, reduced shipping costs and time benefit not only regional vaccine acquisition and production, but in-country distribution of the vaccines and treatments.

---


logistic capabilities, challenging for most developing regions of the world. Inadequate basic infrastructure could cause additional wastage, e.g., blackouts that affect temperature-controlled equipment.  

Following the 2015-2020 Regional Immunization Action Plan, Latin America and the Caribbean region has expanded cold-chain operations in recent years. Yet, bottlenecks remain. Large parts of the region are not equipped for downstream distribution at the unprecedented scale required to address the current health crisis. Distributing vaccines and other lifesaving products in a safe, efficient, and equitable manner will require additional investments and creative solutions.

The various trade facilitation measures that expedite imports (described in the previous section) will be the first step. Then, new partnerships with qualified operators of refrigerated transportation will be conducive to furthering in-country deployment, especially in the last mile. This should include supply chain leaders in other sectors—such as retail and consumer goods—capable of adapting current cold-chain operations to pharmaceutical needs while ensuring safety. Serving remote areas with limited infrastructure will require additional precision in demand planning and pooling. For instance, prioritizing clinics in relatively accessible locations (and schedules) can accelerate vaccine administration and maximize utilization, thus reducing pressure on storage and personnel.

Access

With acquisition and distribution plans in place for vaccines and treatments, Latin America and the Caribbean region must also ensure maximal utilization of these lifesaving products among populations. A patient-centric approach is critical to identifying specific hurdles in each country and designing effective countermeasures.

Supported by the Pan American Health Organization (PAHO) and its Revolving Fund, the Americas region has made significant progress in immunization, currently boasting one of the highest vaccine coverage levels in the world. Many countries have carried out large-scale vaccinations, e.g., Brazil’s national immunization program (Programa Nacional de Imunizações) is able to vaccinate around three hundred million people per year. However, considerable heterogeneity exists both across and within countries. At the subnational level, hard-to-reach areas tend to encounter greater resource and informational constraints to receive or properly administer vaccines, a challenge exacerbated by logistic hurdles mentioned earlier. At the national level, according to a 2018 survey, public skepticism about vaccines varied from between 3 percent to 5 percent of respondents in Argentina to between 15 percent and 17 percent in Peru.

Vaccine and overall medical hesitancy may derive from numerous factors: cultural norms, legislation, health literacy levels, personal experiences, among others. Awareness and educational campaigns can help mitigate some of these issues, especially in combating misinformation around vaccines, treatments, and the ongoing pandemic. Timely and accurate information sharing is key to enhancing public readiness for inoculation, as well as managing expectations. To this end, public and private sectors must cooperate and share medical updates, pricing, timelines, risks, and other information with each other. Together, they must better communicate the relevant information to the public.

Pricing, for instance, will be a fundamental determinant of patient access in many countries. A delicate balance must be struck between patient accessibility and commercial viability. Based on public sources, the expected market prices of some of the most advanced vaccine candidates as of October are: AstraZeneca/Oxford (between $3 and $4 per dose), Johnson & Johnson ($10), BioNTech/Pfizer ($39), and Moderna ($37). Treatments are

likely more expensive, with Gilead’s remdesivir—the first FDA-approved COVID-19 treatment for emergency use—possibly costing between $2,340 and $3,120 for a five-day cycle. Importantly, prices paid by consumers will vary and could be significantly lower, given likely government subsidies and/or insurance coverage. Colombia, for instance, has committed to providing free access to all COVID-19 vaccines acquired and distributed by the government. Generic production could also impact prices. For instance, Gilead voluntarily licensed remdesivir within several Latin American markets, enabling the licensees to set their own prices for the generic product they produce.

As for timelines, recent estimates suggest some vaccine candidates, if approved, could be available for public use in the first half of 2021. However, widespread vaccination will take longer and can push well into 2022. Additional uncertainties could further impact the final cost and timeline of inoculation. Most vaccine front-runners as of late October require two doses separated by several weeks. How feasible is tracking and follow-up after the first injection? Can vaccines generate long-lasting immunity, or would multiple rounds of vaccination be needed to ensure protection? While the humanitarian urgency has propelled several companies to sell at lower-than-usual prices, is this commercially viable over the medium/longer term? How might viral mutations affect the efficacy and safety of vaccines?

of current vaccines? Countries must plan, budget, prepare, and communicate about these issues accordingly.

Relatedly, another key element of a well-organized vaccination strategy is the definition of “priority groups.” Given limited global availability of vaccines (and treatments) in the initial phase, shipments are expected to arrive in waves and in relatively small quantities. The first waves will be unable to meet overall demand. Countries must prioritize access by weighing needs and risks of population groups. There is a broad global consensus giving precedence to vulnerable populations and frontline medical workers, but classifications of each group may differ based on demographics, health conditions, and economic realities of each country. The WHO’s Prioritization Roadmap provides a useful framework for this analysis, including nuanced recommendations across different stages of vaccine availability and epidemiologic scenarios.38

In sum, overcoming access and utilization challenges associated with COVID-19 vaccines necessitates a holistic plan for acquisition, distribution, and readiness. PAHO and the WHO, among other organizations, are actively providing technical and operational support for countries to smooth out vaccine introduction.39 Some regional governments are already thinking ahead. Colombia, for instance, has committed $213 million to the global COVAX Facility to secure vaccines for ten million people, in addition to direct bilateral negotiations with pharmaceutical companies.40 The Colombian government will also spend up to $78 million to facilitate in-country distribution and access of vaccines through improved transport, information campaigns, regional warehouse expansions, and personnel.41

OTHER ISSUES

In addition to the four issues above (production, acquisition, distribution, and access), five other factors could shape the region’s COVID-19 vaccine readiness, as well as its transition towards a more sustainable and efficient post-COVID health model. These five factors are: funding, regulations, politics, multilateral cooperation, and non-COVID-19 conditions.

Funding

Combating the health consequences of COVID-19 alone will require significant funding from governments in the region, from managing outbreaks and quarantines to acquiring and distributing eventual vaccines and treatments. As of May, the region was already spending 2.4 percent of GDP on health and economic responses (still below the 3.7 percent global average).42 In the short and medium term, increased health expenditures will be difficult to juggle in the context of tightening fiscal positions and a likely arduous economic recovery in Latin America. Most countries will not recover to pre-pandemic GDP levels until 2025.43

Over the long run, however, Latin America must confront and resolve chronic underinvestment in health systems, a critical preexisting vulnerability accentuated by COVID-19. Greater budgetary allocation toward health, combined with smart, efficient, and transparent spending, can boost the region’s public health and socioeconomic well-being, while better preparing it for the next pandemic. For example, scaling preventive care—as opposed to curative interventions—lowers medical bills for both patients and governments and simultaneously improves health outcomes. The same applies for transparent procurement of medical and

42 Cobb, “As it hits.”
pharmaceutical products, which can be prone to corruption and counterfeiting in the event of lax oversight. When appropriate, mobilizing private sector resources and well-designed public-private partnerships can complement and expand the traditional public provision of health goods and services.

**Regulations**

Another way to alleviate resource constraints facing the region is through regulatory enhancements. Streamlined regulations in health, trade, and other areas will create efficiency gains needed to better cope with the historic urgency of the crisis. The objective is to strengthen health ecosystems, reducing the time and cost of pandemic response without sacrificing the quality of medical products and services. For instance, fast tracking (pre-) approvals, while ensuring safety, will accelerate production and distribution of successful vaccines. Many regulatory agencies in the region approve new drugs on an average minimum of twelve months. During and even before the pandemic, steps are being taken to shorten this time frame. Colombia’s National Food and Drug Surveillance Institute (Instituto Nacional de Vigilancia de Medicamentos y Alimentos or INVIMA) was able to cut it down to eleven months from twenty-nine months. Brazil’s National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária or ANVISA) has established faster regulatory pathways for approving diagnostics and medical devices.

Regulatory convergence and collaboration across countries can generate additional quick wins. Harmonizing customs regulations and processes, from product-specific certifications and requirements (e.g., packaging and bottling) to classifications of essential versus nonessential goods, can boost intra-regional trade in medical products at this critical juncture. The pandemic has forced countries to temporarily lock down and reopen at different times and durations, causing disruptions in cross-border trade flows and travel. Improved regional coordination can help anticipate and mitigate the impact of such desynchronization on citizens and businesses. Together, these and other measures stand to benefit not only patients and the medical community, but other sectors of the economy that rely on international trade. 

---


and Uruguay, have risen amid the pandemic, despite diverging policies and national contexts. Power dynamics between local and central governments are evolving, in part driven by pandemic-specific circumstances. The need for effective resource allocation and swift decision-making resulted in a relative weakening of local authorities in some cases, and a strengthening in others.

Protests of varying degrees broke out across the region, rooted in fresh discontent caused by COVID-19 or preexisting socioeconomic issues amplified by the pandemic. Neither set of underlying issues should be ignored. Systemic corruption, multidimensional inequality, and disinflation, for instance, could hinder the ongoing pandemic responses and the rapid, equitable access of eventual vaccines and treatments. Government capacity and credibility will make or break the rollout of these and other lifesaving products in Latin America. At this critical juncture, policymakers must also resist the temptation of party politics and unite against the common enemy, an unprecedented pandemic that does not discriminate based on politics.

The politicization of the pandemic is also playing out beyond national borders, impairing an already vulnerable and ailing international system. From the role of the WHO to cross-border medical donations and assistance, geopolitical competition and concerns have complicated a much-needed global coordination of efforts against the virus. Some frictions will likely linger during the vaccine phase.

A multi-stakeholder effort is needed to curb political and other distortions of science. As Latin American governments consider potential vaccines and treatments—whether from the United States, the EU, China, Russia, or elsewhere—the foremost considerations should be health and science-based: safety, efficacy, and transparency. Multilateral and nongovernmental organizations and initiatives can help provide valuable guidance in this regard. When in doubt, citizens and patients must turn to professionals and reputable health authorities for medical advice, instead of relying on unsubstantiated information. Social media platforms should continue to stem COVID-19-related disinformation and misinformation, especially in Latin America where unproven drugs and treatments have gained traction in numerous countries, at times abetted by politically motivated messaging.

### Multilateral Cooperation

Multilateral coordination and assistance have been critical during the ongoing pandemic, from supporting outbreak control to mitigating the effects of famine and economic collapse. Such coordination will be equally important in a much-anticipated transition toward post-pandemic life, made possible by vaccines and treatments.

Promising progress has already been made through multilateral initiatives such as the COVAX Facility. The COVAX Facility aims to secure and equitably provide $2-billion-worth doses of COVID-19 vaccines to participating countries by the end of 2021. On the demand side, COVAX pools demand from countries and negotiates with manufacturers on their behalf, thus ensuring affordable prices through scale. On the supply side, COVAX works with a diversified portfolio of eighteen vaccine candidates to increase the probability of success and availability.

When the eventual vaccines first become available, manufacturing capacity will inevitably lag behind demand. Bidding wars and hoarding could cause global shortages and unequal access—as with PPE and ventilators at the beginning of the pandemic—with less resourceful countries bearing the brunt. The COVAX Facility will help mitigate these problems during this acute phase of demand-supply mismatch. All participating countries are expected to receive enough doses from COVAX to inoculate between 10 percent and 30 percent of their population (based on their own requests) over time. Most Latin American members opted for 20 percent or above.

As of November, one hundred and eighty-six economies had joined COVAX, including ninety-four higher-income economies (self-financed participants paying full prices) and ninety-two low and middle-income economies eligible to be subsidized by Gavi’s Advance Market Commitment (AMC). For many countries in the latter group, COVAX represents their best chance at rapid and affordable access to safe and effective COVID-19 vaccines. Latin American and Caribbean participation has been enthusiastic from the outset. Twenty-two nations from the region have joined. In addition, investors from Mexico and Panama have provided financial contribution to

---


50 COVAX, “Commitment.”
support the work of CEPI, which coordinates vaccine research, development, and manufacturing for the COVAX Facility.

A truly global effort, the COVAX Facility is made possible by member countries, pharmaceutical companies, public and private sector donors (such as the EU and the Bill & Melinda Gates Foundation), and a network of partners (PAHO, the Inter-American Development Bank, the World Bank, various UN agencies, and many others). Going forward, additional support from non-member countries such as the United States could help ensure the continued success of the program, which needs an additional $5 billion in funding in 2021.51 Complementary efforts by national and subnational governments, multilateral organizations, and NGOs—from logistic support to combating disinformation—have the potential to enhance vaccine readiness in Latin America, thus laying the groundwork for successful vaccine introduction in-country.

Non-COVID-19 Conditions

The pandemic has overwhelmed health systems in dangerous yet under-studied ways. Seeing the pandemic from patients’ perspective, countries must refrain from considering action plans for COVID-19 control, treatment, and prevention in a silo. Inundated health facilities have impacted treatments, diagnostics, follow-ups, and overall attention to non-COVID-19 conditions. The delay of care disproportionately affects patients with noncommunicable diseases, who are also particularly

vulnerable to COVID-19. This could be particularly detrimental to Latin America and the Caribbean region, where adult obesity tripled since 1975, leading to heightened risks of cardiovascular illness and diabetes.52 Missed in-person appointments and hospital visits could lead to a spike in these diagnostics in 2021 and 2022, potentially straining health systems once again.

Tackling patient access issues for all patients during and after the COVID-19 pandemic calls for a concerted effort among policymakers, business leaders, and the medical community, including patient advocacy groups. With the pandemic suppressing traditional health service delivery models, an unprecedented opportunity has emerged for collaborating around innovative solutions, such as telemedicine. However, mass telemedicine adoption, while timely, still faces foundational barriers in Latin America. Most of these challenges cannot be solved by the health industry or technology companies alone.

Digital infrastructure upgrades and improved connectivity will be fundamental, especially in rural and other underserved communities. Latin American hospitals and medical professionals can both accelerate and benefit from the widespread implementation of interoperable electronic health records, a telemedicine booster.53 Legislators and regulators must address wide-ranging issues, from data and patient privacy to national and cross-border licensing of medical practitioners. This, coupled with other policy and commercial interventions, will ease practical concerns facing consumers/patients: confidence in the quality of virtual care, reimbursement for telehealth consultations, etc. As a whole, the region can extract important lessons from global experiences and efforts, such as best practices and discussions in the EU on telehealth.54 Despite vast cross-regional differences, many shared challenges and opportunities exist in this emerging space and could accelerate Latin America’s learning curve.

CONCLUSIONS AND RECOMMENDATIONS
As the fight against COVID-19 evolves into a long haul, leaders in Latin America and around the world must mull over next steps. Sustained pandemic measures (testing, social distancing, and selective mobility restrictions) will remain the first line of defense against future infection waves for some time. Even when an effective vaccine becomes available, Latin America should prepare to live with the virus past 2021, given the time needed to ramp up global vaccine production and reach high levels of regional vaccination.

But getting ahead of the persistent virus will also require looking beyond the current phase of the pandemic. Countries should act decisively now to enhance readiness for potential vaccines and therapeutics, thus paving the way for a speedy post-pandemic recovery.

In this context, this issue brief brought to light nine key policy areas central to proactive vaccine and health planning, covering domestic and international factors from acquisition to access. Taking stock of the above, it prescribes a set of eight cross-cutting recommendations to help policymakers better manage the imminent challenges and strengthen health systems over the long term. These eight recommendations—summarized by the acronym PIER, with each letter representing two recommendations—consist of:

P: Public-private collaboration will be critical across all areas of vaccine acquisition, production, distribution, access, etc. No single government or company can tackle these challenges alone given the unprecedented scale of the crisis and the solutions needed. Policymakers, regulators, industry leaders, patient groups, academia, multilateral organizations, and NGOs should continue to forge partnerships to protect citizens in the region.

I: Patient-centric approach must be at the heart of all solutions. Successful deployment of vaccines and treatments depends on policies and strategies that are attentive to patient pain points and expectations, which vary across and within countries. To the extent possible, health authorities should also begin surveying COVID-19’s effects on care for non-COVID-19


Regional coordination and global collaboration are not mutually exclusive. Global problems require global solutions. Renewed multilateralism—such as the COVAX Facility—can help ensure efficient global production and acquisition of vaccines and other lifesaving products, as well as their fair and equitable distribution and access both across and within borders. But global collaboration should not come at the expense of regional integration, or vice versa. Latin American and Caribbean governments should reject the false dichotomy of global-versus-regional/national solutions, which emerged across the globe at the early stage of the pandemic characterized by PPE shortages and isolationism.

Regulatory enhancements and convergence must rise to the challenge. COVID-19 has taken a monumental toll on global health, but it has also triggered a series of equally extraordinary scientific breakthroughs. In a race against time, unprecedented R&D and partnerships compressed vaccine development processes from years to months. Policymakers and regulators must also proactively adapt to the circumstances. Where needed and while ensuring safety, government authorities must expedite internal (pre-)approvals and harmonize pertinent regulations across borders. A streamlined, predictable, and forward-thinking regulatory environment is vital to safeguarding public health in the immediate future, as well as fostering regional innovation and long-term competitiveness.

Finally, the ongoing pandemic represents a unique learning opportunity and a possible health inflection point in the region, especially along the lines of the PIER recommendations above. Going back to the pre-pandemic normal will not be enough. Health systems need to be reinforced to prevent and better cope with the next pandemic. Despite great regional heterogeneity, perhaps the single biggest challenge and opportunity will be to transform the current health-focused policy momentum into longer-term actions and priorities. While most governments may not have the luxury to act on this at the moment, the Atlantic Council, through this and other writings, encourages governments—and relevant private, multilateral, and other stakeholders—to proactively (re)imagine a post-pandemic health agenda in the time ahead.

---


ACKNOWLEDGMENT

In Latin America, combating the devastating health and socio-economic consequences of COVID-19 requires unprecedented actions and collaboration among relevant stakeholders. The urgency has propelled the Atlantic Council’s Adrienne Arsht Latin America Center to provide timelier-than-ever insights and policy recommendations to support the region during and beyond the pandemic. This issue brief—focusing on vaccine and other associated health policy issues—constitutes part of this broader effort. The policy decisions made in the region today will have repercussions for months and years to come.

I would like to thank our Center Director Jason Marczak for his guidance and leadership, and to other team members, Camila Hernandez, Cristina Guevara, Sara Van Velkinburgh, and Gabriella Cova for their research and coordination support for this report. I am grateful for the invaluable insights from over 40 recognized experts and stakeholders which greatly enriched the issue brief. Collectively, they represented a wide-ranging issue-specific and cross-cutting expertise, as well as diverse perspectives from the public, private, multilateral, academic, and NGO sectors in Latin America and beyond. Lastly, I would like to acknowledge colleagues from FTI Consulting for their partnership and generous support for making this project possible, in particular, Ana Heeren and Andres Garcia Pelaez.

Pepe Zhang
Associate Director, Adrienne Arsht Latin America Center
Atlantic Council

ABOUT THE AUTHOR

Pepe Zhang is an associate director at the Atlantic Council’s Adrienne Arsht Latin America Center. Zhang leads the Center’s policy efforts in understanding and countering COVID-19’s multi-dimensional impact on Latin America, while co-coordinating its work on other broader regional economic issues such as international trade and investment, supply chain shifts, and macroeconomics. In addition, Zhang manages the Center’s China-Latin America portfolio, which provides timely insight on the growing relations through multi-perspective analyses and events. Zhang has provided multi-lingual commentary on these issues through frequent speaking engagements as well as to US and international press outlets including CNN, New York Times, Associated Press, Valor Econômico, and O Globo.

Prior to joining the Atlantic Council, Zhang worked at the Inter-American Development Bank, focusing on international trade and investment promotion, entrepreneurship, and technology in Latin America and the Caribbean. Zhang holds a master’s degree in international economics from the Johns Hopkins University’s Paul Nitze School of Advanced International Studies (SAIS), and a bachelor’s degree from Pomona College in Latin American Politics and Spanish. Zhang is fluent in Spanish, English, and Chinese, and has extensive professional and academic experience across Latin America, China, and the United States.
Atlantic Council Board of Directors

CHAIRMAN
*John F.W. Rogers

EXECUTIVE CHAIRMAN
*James L. Jones

EMERITUS

PRESIDENT AND CEO
*Frederick Kempe

EXECUTIVE VICE CHAIRS
*Adrienne Arsht
*Stephen J. Hadley

VICE CHAIRS
*Robert J. Abernethy
*Richard W. Edelman
*C. Boyden Gray
*Alexander V. Mirtchev
*John J. Studzinski

TREASURER
*George Lund

SECRETARY
*Walter B. Slocombe

DIRECTORS
Stéphane Abrial
Odeh Aburdene
Todd Achilles
*Peter Ackerman
Timothy D. Adams
*Michael Andersson
David D. Aufhauser
Colleen Bell
Matthew C. Bernstein
*Rafic A. Bizri
Linden P. Blue
Philip M. Breedlove
Myron Brilliant
*Esther Brimmer
R. Nicholas Burns
*Richard R. Burt
Michael Calvey
Teresa Carlson
James E. Cartwright
John E. Chapoton
Ahmed Charai
Melanie Chen
Michael Chertoff
*George Chopivsky
Wesley K. Clark
*Helima Croft
Ralph D. Crosby, Jr.
*Ankit N. Desai
Dario Deste
Paula J. Dobriansky
Joseph F. Dunford, Jr.
Thomas J. Egan, Jr.
Stuart E. Eizenstat
Thomas R. Eldridge
*Alan H. Fleischmann
Jendayi E. Frazer
Courtney Geduldig
Robert S. Gelbard
Thomas H. Glocer
John B. Goodman
*Sherri W. Goodman
Murathan Güral
*Amir A. Handjani
Katie Harbath
John D. Harris, II
Frank Haun
Michael V. Hayden
Amos Hochstein
*Karl V. Hopkins
Andrew Hove
Mary L. Howell
Ian Ihnatowycz
Wolfgang F. Ischinger
Deborah Lee James
Joia M. Johnson
Stephen R. Kappes
*Maria Pica Karp
Andre Kelleners
Astri Kimball Van Dyke
Henry A. Kissinger
*C. Jeffrey Knittel
Franklin D. Kramer
Laura Lane
Jan M. Lodal
Douglas Lute
Jane Holl Lute
William J. Lynn
Mian M. Mansha
Marco Margheri
Chris Marlin
William Marron
Neil Masterson
Gerardo Mato
Timothy McBride
Elin McGrain
John M. McHugh
H.R. McMaster
Eric D.K. Melby
*Judith A. Miller
Dariusz Mioduski
*Michael J. Morell
*Richard Morningstar
Virginia A. Mulberger
Mary Claire Murphy
Edward J. Newberry
Thomas R. Nides
Franco Nuschese
Joseph S. Nye
Hilda Ochoa-Brillembourg
Ahmet M. Ören
Sally A. Painter
*Ana I. Palacio
*Kostas Pantazopoulos
Carlos Pascual
Alan Pellegrini
David H. Petraeus
W. DeVier Pierson
Lisa Pollina
Daniel B. Poneman
*Dina H. Powell McCormick
Robert Rangel
Thomas J. Ridge
Lawrence Di Rita
Michael J. Rogers
Charles O. Rossotti
Harry Sachinis
C. Michael Scarparotti
Rajiv Shah

STEPHEN SHAPIRO
Wendy Sherman
Kris Singh
Christopher Smith
James G. Stavridis
Michael S. Steele
Richard J.A. Steele
Mary Streett
Frances M. Townsend
Clyde C. Tugle
Melanne Verveer
Charles F. Wald
Michael F. Walsh
Gine Wang-Reese
Ronald Weiser
Olin Wethington
Maciej Witucki
Neal S. Wolin
Jenny Wood
Guang Yang
Mary C. Yates
Dov S. Zakheim

HONORARY DIRECTORS
James A. Baker, III
Ashton B. Carter
Robert M. Gates
James N. Mattis
Michael G. Mullen
Leon E. Panetta
William J. Perry
Colin L. Powell
Condoleezza Rice
George P. Shultz
Horst Teltschik
John W. Warner
William H. Webster

*Executive Committee Members

List as of November 6, 2020
The Atlantic Council is a nonpartisan organization that promotes constructive US leadership and engagement in international affairs based on the central role of the Atlantic community in meeting today’s global challenges.

© 2020 The Atlantic Council of the United States. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without permission in writing from the Atlantic Council, except in the case of brief quotations in news articles, critical articles, or reviews. Please direct inquiries to:

Atlantic Council

1030 15th Street, NW, 12th Floor,
Washington, DC 20005